Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer

Molecules

Volumn 19, Issue 9, 2014, Pages 15196-15212

  Schroeder, Richard L ^a   Stevens, Cheryl L ^b   Sridhar, Jayalakshmi ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

^b WESTERN KENTUCKY UNIVERSITY   (United States)

Author keywords

HER2 inhibition; Human epidermal growth factor 2 (HER2); Kinase domain; Monoclonal antibodies; Small molecule inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMISTRY; FEMALE; HUMAN;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2;

EID: 84907439121     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules190915196     Document Type: Review

References (88)

1. Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A.; et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
2. Bacus, S.S.; Zelnick, C.R.; Plowman, G.; Yarden, Y. Expression of the erbb-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. Am. J. Clin. Pathol. 1994, 102, S13-S24.
3. Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
4. Pegram, M.D.; Lipton, A.; Hayes, D.F.; Weber, B.L.; Baselga, J.M.; Tripathy, D.; Baly, D.; Baughman, S.A.; Twaddell, T.; Glaspy, J.A.; et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 1998, 16, 2659-2671.
5. Arteaga, C.L. Progress in breast cancer: Overview. Clin. Cancer Res. 2013, 19, 6353-6359.
6. Zhang, X.H.; Giuliano, M.; Trivedi, M.V.; Schiff, R.; Osborne, C.K. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin. Cancer Res. 2013, 19, 6389-6397.
7. Yarden, Y.; Sliwkowski, M.X. Untangling the erbb signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2, 127-137.
8. Hynes, N.E.; Lane, H.A. Erbb receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341-354.
9. Olayioye, M.A.; Graus-Porta, D.; Beerli, R.R.; Rohrer, J.; Gay, B.; Hynes, N.E. Erbb-1 and erbb-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell. Biol. 1998, 18, 5042-5051.
10. Lenferink, A.E.; Pinkas-Kramarski, R.; van de Poll, M.L.; van Vugt, M.J.; Klapper, L.N.; Tzahar, E.; Waterman, H.; Sela, M.; van Zoelen, E.J.; Yarden, Y. Differential endocytic routing of homo-and hetero-dimeric erbb tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 1998, 17, 3385-3397.
11. Tural, D.; Akar, E.; Mutlu, H.; Kilickap, S. P95 HER2 fragments and breast cancer outcome. Expert Rev. Anticancer Ther. 2014, 1-8.
12. Arribas, J.; Baselga, J.; Pedersen, K.; Parra-Palau, J.L. P95HER2 and breast cancer. Cancer Res. 2011, 71, 1515-1519.
13. Hojjat-Farsangi, M. Small-molecule inhibitors of the receptor tyrosine kinases: Promising tools for targeted cancer therapies. Int. J. Mol. Sci. 2014, 15, 13768-13801.
14. Norman, P. Inducible tyrosine kinase inhibitors: A review of the patent literature (2010-2013). Expert Opin. Ther. Pat. 2014, 24, 979-991.
15. Roskoski, R., Jr. Erbb/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Pharmacol. Res. 2014, 87C, 42-59.
16. Cui, J.J. Targeting receptor tyrosine kinase met in cancer: Small molecule inhibitors and clinical progress. J. Med. Chem. 2014, 57, 4427-4453.
17. Anandappa, G.; Turner, N.C. Targeting receptor tyrosine kinases in HER2-negative breast cancer. Curr. Opin. Oncol. 2013, 25, 594-601.
18. Warnault, P.; Yasri, A.; Coisy-Quivy, M.; Cheve, G.; Bories, C.; Fauvel, B.; Benhida, R. Recent advances in drug design of epidermal growth factor receptor inhibitors. Curr. Med. Chem. 2013, 20, 2043-2067.
19. Ocana, A.; Pandiella, A. Targeting HER receptors in cancer. Curr. Pharm. Des. 2013, 19, 808-817.
20. Arteaga, C.L.; Sliwkowski, M.X.; Osborne, C.K.; Perez, E.A.; Puglisi, F.; Gianni, L. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat. Rev. Clin. Oncol. 2011, 9, 16-32.
21. Saini, K.S.; Azim, H.A., Jr.; Metzger-Filho, O.; Loi, S.; Sotiriou, C.; de Azambuja, E.; Piccart, M. Beyond trastuzumab: New treatment options for HER2-positive breast cancer. Breast 2011, 20 (Suppl. 3), S20-S27.
22. Nielsen, D.L.; Kümler, I.; Palshof, J.A.; Andersson, M. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 2013, 22, 1-12.
23. Baselga, J.; Tripathy, D.; Mendelsohn, J.; Baughman, S.; Benz, C.C.; Dantis, L.; Sklarin, N.T.; Seidman, A.D.; Hudis, C.A.; Moore, J.; et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 1996, 14, 737-744.
24. Cobleigh, M.A.; Vogel, C.L.; Tripathy, D.; Robert, N.J.; Scholl, S.; Fehrenbacher, L.; Wolter, J.M.; Paton, V.; Shak, S.; Lieberman, G.; et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999, 17, 2639-2648.
25. Piccart-Gebhart, M.J.; Procter, M.; Leyland-Jones, B.; Goldhirsch, A.; Untch, M.; Smith, I.; Gianni, L.; Baselga, J.; Bell, R.; Jackisch, C.; et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353, 1659-1672.
26. Romond, E.H.; Perez, E.A.; Bryant, J.; Suman, V.J.; Geyer, C.E., Jr.; Davidson, N.E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P.A.; et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353, 1673-1684.
27. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344, 783-792.
28. Esteva, F.J.; Valero, V.; Booser, D.; Guerra, L.T.; Murray, J.L.; Pusztai, L.; Cristofanilli, M.; Arun, B.; Esmaeli, B.; Fritsche, H.A.; et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20, 1800-1808.
29. O?Shaughnessy, J.A.; Vukelja, S.; Marsland, T.; Kimmel, G.; Ratnam, S.; Pippen, J.E. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin. Breast Cancer 2004, 5, 142-147.
30. Pegram, M.D.; Konecny, G.E.; O?Callaghan, C.; Beryt, M.; Pietras, R.; Slamon, D.J. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer Inst. 2004, 96, 739-749.
31. Seidman, A.D.; Fornier, M.N.; Esteva, F.J.; Tan, L.; Kaptain, S.; Bach, A.; Panageas, K.S.; Arroyo, C.; Valero, V.; Currie, V.; et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. 2001, 19, 2587-2595.
32. Baselga, J.; Albanell, J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 2001, 12, S35-S41.
33. Dokmanovic, M.; Wu, J.W. Mechanisms of trastuzumab resistance and opportunities to overcome therapeutic resistance. J. Mol. Biomark. Diagn. 2013, 4, doi:10.4172/2155-9929.1000e116.
34. Abraham, J.; Stenger, M. Pertuzumab in neoadjuvant treatment of HER2-positive early breast cancer. J. Community Support. Oncol. 2014, 12, 84-86.
35. Kang, Y.K.; Rha, S.Y.; Tassone, P.; Barriuso, J.; Yu, R.; Szado, T.; Garg, A.; Bang, Y.J. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br. J. Cancer 2014, 111, 660-666.
36. Boix-Perales, H.; Borregaard, J.; Jensen, K.B.; Ersboll, J.; Galluzzo, S.; Giuliani, R.; Ciceroni, C.; Melchiorri, D.; Salmonson, T.; Bergh, J.; et al. The european medicines agency review of pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: Summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2014, 19, 766-773.
37. Noble, M.E.; Endicott, J.A.; Johnson, L.N. Protein kinase inhibitors: Insights into drug design from structure. Science 2004, 303, 1800-1805.
38. Aertgeerts, K.; Skene, R.; Yano, J.; Sang, B.C.; Zou, H.; Snell, G.; Jennings, A.; Iwamoto, K.; Habuka, N.; Hirokawa, A.; et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J. Biol. Chem. 2011, 286, 18756-18765.
39. Qiu, C.; Tarrant, M.K.; Choi, S.H.; Sathyamurthy, A.; Bose, R.; Banjade, S.; Pal, A.; Bornmann, W.G.; Lemmon, M.A.; Cole, P.A.; et al. Mechanism of activation and inhibition of the HER4/erbb4 kinase. Structure 2008, 16, 460-467.
40. Zhang, X.; Gureasko, J.; Shen, K.; Cole, P.A.; Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125, 1137-1149.
41. Zhang, X.; Pickin, K.A.; Bose, R.; Jura, N.; Cole, P.A.; Kuriyan, J. Inhibition of the egf receptor by binding of mig6 to an activating kinase domain interface. Nature 2007, 450, 741-744.
42. Zhou, Y.; Li, S.; Hu, Y.P.; Wang, J.; Hauser, J.; Conway, A.N.; Vinci, M.A.; Humphrey, L.; Zborowska, E.; Willson, J.K.; et al. Blockade of EGFR and erbB2 by the novel dual EGFR and erbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma geo cells to apoptosis. Cancer Res. 2006, 66, 404-411.
43. Moulder, S.L.; Yakes, F.M.; Muthuswamy, S.K.; Bianco, R.; Simpson, J.F.; Arteaga, C.L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001, 61, 8887-8895.
44. Piccart-Gebhart, M.J.; Holmes, A.P.; Baselga, J.; Azambuja, E.D.; Dueck, A.C.; Viale, G.; Zujewski, J.A.; Goldhirsch, A.; Santillana, S.; Pritchard, K.I.; et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T?L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J. Clin. Oncol. 2014, 32 (Suppl.), 5s, Abstract LBA4.
45. Geuna, E.; Montemurro, F.; Aglietta, M.; Valabrega, G. Potential of afatinib in the treatment of patients with HER2-positive breast cancer. Breast Cancer (Dove Med. Press) 2012, 4, 131-137.
46. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L.R.; Padera, R.F.; Shapiro, G.I.; Baum, A.; Himmelsbach, F.; et al. Bibw2992, an irreversible egfr/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27, 4702-4711.
47. Katakami, N.; Atagi, S.; Goto, K.; Hida, T.; Horai, T.; Inoue, A.; Ichinose, Y.; Koboyashi, K.; Takeda, K.; Kiura, K.; et al. Lux-lung 4: A phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. 2013, 31, 3335-3341.
48. Eskens, F.A.; Mom, C.H.; Planting, A.S.; Gietema, J.A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; et al. A phase I dose escalation study of bibw 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (egfr) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer 2008, 98, 80-85.
49. Yap, T.A.; Vidal, L.; Adam, J.; Stephens, P.; Spicer, J.; Shaw, H.; Ang, J.; Temple, G.; Bell, S.; Shahidi, M.; et al. Phase I trial of the irreversible egfr and HER2 kinase inhibitor bibw 2992 in patients with advanced solid tumors. J. Clin. Oncol. 2010, 28, 3965-3972.
50. Barlaam, B.; Anderton, J.; Ballard, P.; Bradbury, R.H.; Hennequin, L.F.; Hickinson, D.M.; Kettle, J.G.; Kirk, G.; Klinowska, T.; Lambert-van der Brempt, C.; et al. Discovery of azd8931, an equipotent, reversible inhibitor of signaling by egfr, HER2, and HER3 receptors. ACS Med. Chem. Lett. 2013, 4, 742-746.
51. Mu, Z.; Klinowska, T.; Dong, X.; Foster, E.; Womack, C.; Fernandez, S.V.; Cristofanilli, M. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: Preclinical activity in HER2 non-amplified inflammatory breast cancer models. J. Exp. Clin. Cancer Res. 2014, 33,47.
52. . Kurata, T.; Tsurutani, J.; Fujisaka, Y.; Okamoto, W.; Hayashi, H.; Kawakami, H.; Shin, E.; Hayashi, N.; Nakagawa, K. Inhibition of egfr, HER2 and HER3 signaling with azd8931 alone and in combination with paclitaxel: Phase I study in japanese patients with advanced solid malignancies and advanced breast cancer. Investig. New Drugs 2014, doi:10.1007/s10637-014-0112-7.
53. Tjulandin, S.; Moiseyenko, V.; Semiglazov, V.; Manikhas, G.; Learoyd, M.; Saunders, A.; Stuart, M.; Keilholz, U. Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Investig. New Drugs 2014, 32, 145-153.
54. Xie, H.; Lin, L.; Tong, L.; Jiang, Y.; Zheng, M.; Chen, Z.; Jiang, X.; Zhang, X.; Ren, X.; Qu, W.; et al. Ast1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One 2011, 6, e21487.
55. Zhang, J.; Cao, J.; Li, J.; Zhang, Y.; Chen, Z.; Peng, W.; Sun, S.; Zhao, N.; Wang, J.; Zhong, D.; et al. A phase I study of ast1306, a novel irreversible egfr and HER2 kinase inhibitor, in patients with advanced solid tumors. J. Hematol. Oncol. 2014, 7,22.
56. . Berezowska, S.; Diermeier-Daucher, S.; Brockhoff, G.; Busch, R.; Duyster, J.; Grosu, A.L.; Schlegel, J. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor aee788 on the resistance to specific egfr inhibition in glioma cells. Int. J. Mol. Med. 2010, 26, 713-721.
57. Evans, A.H.; Pancholi, S.; Farmer, I.; Thornhill, A.; Evans, D.B.; Johnston, S.R.; Dowsett, M.; Martin, L.A. EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ERpositive breast cancer cells but functions synergistically with endocrine therapy. Br. J. Cancer 2010, 102, 1235-1243.
58. Ako, E.; Yamashita, Y.; Ohira, M.; Yamazaki, M.; Hori, T.; Kubo, N.; Sawada, T.; Hirakawa, K. The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo. Oncol. Rep. 2007, 17, 887-893.
59. Rixe, O.; Franco, S.X.; Yardley, D.A.; Johnston, S.R.; Martin, M.; Arun, B.K.; Letrent, S.P.; Rugo, H.S. A randomized, phase II, dose-finding study of the pan-erbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother. Pharmacol. 2009, 64, 1139-1148.
60. Jani, J.P.; Finn, R.S.; Campbell, M.; Coleman, K.G.; Connell, R.D.; Currier, N.; Emerson, E.O.; Floyd, E.; Harriman, S.; Kath, J.C.; et al. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. Cancer Res. 2007, 67, 9887-9893.
61. Munster, P.N.; Britten, C.D.; Mita, M.; Gelmon, K.; Minton, S.E.; Moulder, S.; Slamon, D.J.; Guo, F.; Letrent, S.P.; Denis, L.; et al. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin. Cancer Res. 2007, 13, 1238-1245.
62. Cai, X.; Zhai, H.X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C.J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J. Med. Chem. 2010, 53, 2000-2009.
63. Lai, C.J.; Bao, R.; Tao, X.; Wang, J.; Atoyan, R.; Qu, H.; Wang, D.G.; Yin, L.; Samson, M.; Forrester, J.; et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 2010, 70, 3647-3656.
64. Jimeno, A.; Galloway, T.; Wirth, L.; Gilbert, J.; Saba, N.; Bauman, J.; Colevas, D.; Mehra, R.; Raben, D.; Lai, C.-J.; et al. A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck. Mol. Cancer Ther. 2013, 12 (Suppl. 11), doi:10.1158/1535-7163.TARG-13-B268.
65. Ishikawa, T.; Seto, M.; Banno, H.; Kawakita, Y.; Oorui, M.; Taniguchi, T.; Ohta, Y.; Tamura, T.; Nakayama, A.; Miki, H.; et al. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J. Med. Chem. 2011, 54, 8030-8050.
66. Erdo, F.; Gordon, J.; Wu, J.T.; Sziraki, I. Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats. Brain Res. Bull. 2012, 87, 413-419.
67. Doi, T.; Takiuchi, H.; Ohtsu, A.; Fuse, N.; Goto, M.; Yoshida, M.; Dote, N.; Kuze, Y.; Jinno, F.; Fujimoto, M.; et al. Phase I first-in-human study of tak-285, a novel investigational dual HER2/egfr inhibitor, in cancer patients. Br. J. Cancer 2012, 106, 666-672.
68. Torres, M.A.; Raju, U.; Molkentine, D.; Riesterer, O.; Milas, L.; Ang, K.K. Ac480, formerly bms-599626, a pan HER inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Investig. New Drugs 2011, 29, 554-561.
69. Axelrod, M.J.; Mendez, R.E.; Khalil, A.; Leimgruber, S.S.; Sharlow, E.R.; Capaldo, B.; Conaway, M.; Gioeli, D.G.; Weber, M.J.; Jameson, M.J. Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways. Head Neck 2014, doi:10.1002/hed.23822.
70. Janne, P.A.; Boss, D.S.; Camidge, D.R.; Britten, C.D.; Engelman, J.A.; Garon, E.B.; Guo, F.; Wong, S.; Liang, J.; Letrent, S.; et al. Phase I dose-escalation study of the pan-HER inhibitor, pf299804, in patients with advanced malignant solid tumors. Clin. Cancer Res. 2011, 17, 1131-1139.
71. Kalous, O.; Conklin, D.; Desai, A.J.; O?Brien, N.A.; Ginther, C.; Anderson, L.; Cohen, D.J.; Britten, C.D.; Taylor, I.; Christensen, J.G.; et al. Dacomitinib (pf-00299804), an irreversible pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol. Cancer Ther. 2012, 11, 1978-1987.
72. Reckamp, K.L.; Giaccone, G.; Camidge, D.R.; Gadgeel, S.M.; Khuri, F.R.; Engelman, J.A.; Koczywas, M.; Rajan, A.; Campbell, A.K.; Gernhardt, D.; et al. A phase 2 trial of dacomitinib (pf-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 2014, 120, 1145-1154.
73. Erlichman, C.; Hidalgo, M.; Boni, J.P.; Martins, P.; Quinn, S.E.; Zacharchuk, C.; Amorusi, P.; Adjei, A.A.; Rowinsky, E.K. Phase I study of ekb-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 2006, 24, 2252-2260.
74. Rusnak, D.W.; Lackey, K.; Affleck, K.; Wood, E.R.; Alligood, K.J.; Rhodes, N.; Keith, B.R.; Murray, D.M.; Knight, W.B.; Mullin, R.J.; et al. The effects of the novel, reversible epidermal growth factor receptor/erbb-2 tyrosine kinase inhibitor, gw2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001, 1, 85-94.
75. Barf, T.; Kaptein, A. Irreversible protein kinase inhibitors: Balancing the benefits and risks. J. Med. Chem. 2012, 55, 6243-6262.
76. Traxler, P.; Allegrini, P.R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H.A.; McSheehy, P.; Mestan, J.; et al. AEE788: A dual family epidermal growth factor receptor/erbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004, 64, 4931-4941.
77. Smaill, J.B.; Showalter, H.D.; Zhou, H.; Bridges, A.J.; McNamara, D.J.; Fry, D.W.; Nelson, J.M.; Sherwood, V.; Vincent, P.W.; Roberts, B.J.; et al. Tyrosine kinase inhibitors. 6-substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. J. Med. Chem. 2001, 44, 429-440.
78. Morphy, R. Selectively nonselective kinase inhibition: Striking the right balance. J. Med. Chem. 2010, 53, 1413-1437.
79. Kawakita, Y.; Seto, M.; Ohashi, T.; Tamura, T.; Yusa, T.; Miki, H.; Iwata, H.; Kamiguchi, H.; Tanaka, T.; Sogabe, S.; et al. Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors. Bioorg. Med. Chem. 2013, 21, 2250-2261.
80. Gavai, A.V.; Fink, B.E.; Fairfax, D.J.; Martin, G.S.; Rossiter, L.M.; Holst, C.L.; Kim, S.H.; Leavitt, K.J.; Mastalerz, H.; Han, W.C.; et al. Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1h-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3s)-3-morpholinylmethyl ester (bms-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. J. Med. Chem. 2009, 52, 6527-6530.
81. Fink, B.E.; Norris, D.; Mastalerz, H.; Chen, P.; Goyal, B.; Zhao, Y.; Kim, S.H.; Vite, G.D.; Lee, F.Y.; Zhang, H.; et al. Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of egfr and HER2 protein tyrosine kinases. Bioorg. Med. Chem. Lett. 2011, 21, 781-785.
82. Sadek, M.M.; Serrya, R.A.; Kafafy, A.H.; Ahmed, M.; Wang, F.; Abouzid, K.A. Discovery of new HER2/egfr dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents. J. Enzym. Inhib. Med. Chem. 2014, 29, 215-222.
83. Li, D.D.; Qin, Y.J.; Sun, J.; Li, J.R.; Fang, F.; Du, Q.R.; Qian, Y.; Gong, H.B.; Zhu, H.L. Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual egfr/HER2 tyrosine kinase inhibitors. PLoS One 2013, 8, e69427.
84. Kawakita, Y.; Miwa, K.; Seto, M.; Banno, H.; Ohta, Y.; Tamura, T.; Yusa, T.; Miki, H.; Kamiguchi, H.; Ikeda, Y.; et al. Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/egfr dual inhibitors: Improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy. Bioorg. Med. Chem. 2012, 20, 6171-6180.
85. Kawakita, Y.; Banno, H.; Ohashi, T.; Tamura, T.; Yusa, T.; Nakayama, A.; Miki, H.; Iwata, H.; Kamiguchi, H.; Tanaka, T.; et al. Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: Exploration of novel back-pocket binders. J. Med. Chem. 2012, 55, 3975-3991.
86. Zhou, W.; Ercan, D.; Janne, P.A.; Gray, N.S. Discovery of selective irreversible inhibitors for EGFR-T790M. Bioorg. Med. Chem. Lett. 2011, 21, 638-643.
87. Ok, S.; Kim, S.M.; Kim, C.; Nam, D.; Shim, B.S.; Kim, S.H.; Ahn, K.S.; Choi, S.H. Emodin inhibits invasion and migration of prostate and lung cancer cells by downregulating the expression of chemokine receptor cxcr4. Immunopharmacol. Immunotoxicol. 2012, 34, 768-778.
88. Sridhar, J.; Sfondouris, M.E.; Bratton, M.R.; Nguyen, T.L.; Townley, I.; Klein Stevens, C.L.; Jones, F.E. Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer. Bioorg. Med. Chem. Lett. 2013, 24, 126-131.